mTORC1 targeting by rapalogs could lead to unintended feedback amplification of the PI3K/AKT/mTOR pathway in AML, potentially subverting the clinical effect of targeting mTORC1 alone [4, 5]. Here, AKT1 is linked to acute myeloid leukemia.